Royalty Pharma (RPRX) is expected to release quarterly results on Wednesday

Royalty Pharma (NASDAQ: RPRX) will report its results before the market opens on Wednesday, November 10. Analysts expect the company to report earnings of $ 0.70 per share for the quarter. Those interested in listening to the corporate earnings conference call can do so using this link.

Royalty Pharma (NASDAQ: RPRX) last released its quarterly earnings data on Wednesday August 11. The biopharmaceutical company reported earnings per share (EPS) of $ 0.71 for the quarter, beating the consensus estimate of $ 0.70 of $ 0.01 by Thomson Reuters. The company posted revenue of $ 475.00 million for the quarter, compared to analysts’ expectations of $ 474.52 million. Royalty Pharma recorded a return on equity of 13.02% and a net margin of 43.43%. On average, analysts expect Royalty Pharma to post EPS of $ 3 for the current fiscal year and EPS of $ 3 for the next fiscal year.

RPRX shares opened at $ 38.11 on Wednesday. The stock has a market cap of $ 23.14 billion, a price / earnings ratio of 23.82, a price / earnings-growth ratio of 1.11, and a beta of 0.94. Royalty Pharma has a one-year low at $ 34.86 and a one-year high at $ 53.23. The company’s 50-day simple moving average is $ 37.63 and its 200-day simple moving average is $ 39.99. The company has a debt ratio of 0.56, a current ratio of 9.53, and a rapid ratio of 9.53.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 15. Shareholders of record on Friday, November 19 will receive a dividend of $ 0.17 per share. The ex-dividend date of this dividend is Thursday, November 18. This represents an annualized dividend of $ 0.68 and a dividend yield of 1.78%. Royalty Pharma’s dividend payout ratio (DPR) is 42.24%.

(A d)

Access our premier research platform which includes MarketBeat Daily Premium, portfolio monitoring tools, stock filters, research tools, real-time news feed, email and SMS alerts, MarketBeat idea engine, exclusive brokerage rankings, extensive data export tools and more.

Several brokerage firms have recently published reports on RPRX. Tigress Financial began covering Royalty Pharma in a report on Friday July 30. They set a “buy” rating and a price target of $ 50.00 for the stock. Morgan Stanley lowered its price target for Royalty Pharma from $ 51.00 to $ 46.00 and set a rating of “equal weight” to the stock in a report released on Monday August 16. Citigroup downgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a price target of $ 50.00 on the stock in a report released on Friday, October 29. Finally, Zacks Investment Research downgraded Royalty Pharma from a “buy” rating to a “keep” rating in a report released on Tuesday, October 19. Two analysts rated the stock with a conservation rating and three gave the stock a buy rating. According to, the stock currently has a consensus rating of “Buy” and a consensus target price of $ 47.20.

Meanwhile, director Rory B. Riggs sold 40,000 shares of the company in a transaction that took place on Tuesday, September 28. The stock was sold at an average price of $ 36.75, for a total transaction of $ 1,470,000.00. The transaction was disclosed in a file with the SEC, accessible through this link. Insiders own 25.86% of the company’s shares.

A hedge fund recently increased its stake in the shares of Royalty Pharma. Morgan Stanley increased its stake in Royalty Pharma plc (NASDAQ: RPRX) by 5.6% in the 2nd quarter, according to its latest filing with the Securities & Exchange Commission. The fund held 50,794,041 shares of the biopharmaceutical company after acquiring an additional 2,675,799 shares during the quarter. Morgan Stanley owned approximately 8.37% of Royalty Pharma for a value of $ 2,082,049,000 at the time of its last filing with the Securities & Exchange Commission. 40.55% of the shares are currently held by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. She is also involved in the identification, evaluation and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and non-profit organizations, small and medium-sized biotechnology companies and pharmaceutical companies.

See also: Market performance

Revenue History of Royalty Pharma (NASDAQ: RPRX)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Royalty Pharma now?

Before you consider Royalty Pharma, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of… and Royalty Pharma was not on the list.

Although Royalty Pharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Previous Eileen Tan quit her oil and gas job to start a fashion startup
Next Prince Harry and Meghan Markle's home is surrounded by famous neighbors: Katy Perry, Ellen DeGeneres, more

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *